Abstract
Background In Parkinson’s disease (PD) the propensity to fall and the higher risk of osteoporosis converge yielding a high fracture risk. Updated National Osteoporosis Guideline Group (NOGG) guidance recommends that PD should trigger a risk assessment, for example using the FRAX tool, yet clinical pathways remain sub-optimal. To address this, we generated an algorithm for the assessment and management of bone-health specifically in PD.
Methods Within the Proactive and Integrated Management and Empowerment in Parkinson’s Disease randomised controlled trial (PRIME-UK RCT), bone-health metrics were collected, and all participants were offered a DXA scan. The FRAX tool was used to obtain the 10-year probability of hip and major osteoporotic fracture (MOF), and the resulting NOGG risk- category recorded. Probabilities were recalculated including femoral-neck bone mineral density (FN-BMD) and/or with numeric adjustment for recurrent falls, and results compared.
Results Among 182 people with parkinsonism (mean age 73.8 years, 65% male, median disease duration 5-years), 28.0% reported a prior fragility fracture, and 40.7% recurrent falls over the previous year. 28.6% had MOF above NOGG intervention thresholds (IT); whilst 12.1% had a FN-BMD T-Score ≤-2.5. Recalculation of FRAX with FN-BMD (n=182) reduced fracture MOF and hip fracture probabilities; 12 (6.6%) deescalated below the IT, and 16 (8.8%) moved above the IT.
Conclusions This 2024 BONE-PARK algorithm is informed by both the latest NOGG Guidelines and novel findings in a ‘real-world’ population. The algorithm will aid bone health assessment people with PD.
Key points
Bone-health in Parkinson’s is under-recognised and under-treated, and we have demonstrated an ongoing treatment gap.
In this population, we have demonstrated DXA is feasible but infrequently changes treatment.
Our Parkinson’s specific guidance supports clinicians and patients to recognise, investigate and treat fracture risk.
Competing Interest Statement
The authors have declared no competing interest.
Clinical Trial
NCT05127057
Funding Statement
This trial was funded by Royal Osteoporosis Society (509) Parkinson’s Excellence Network (M-22-004) and Gatsby (GAT3676).
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
Ethical approval was granted by London-Harrow Research Ethics Committee (REC reference 21/LO/0387) on 14/7/2021.
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.
Yes
Data Availability
The participants of this study did not give written consent for their data to be shared publicly, so due to the sensitive nature of the research supporting data is not available.
